Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and has a dismal prognosis. Median age at IPF onset is 60-70 years and it is mainly related to cigarette smoke exposure. Its clinical profile is heterogeneous and different clinical phenotypes are now better defined: familial IPF, slow and rapid progressors, combined pulmonary fibrosis and emphysema, anti-neutrophil cytoplasmic antibodies/microscopic polyangiitis and IPF, and IPF associated with lung cancer. Acute exacerbation associated with rapid functional decline is an event that does not happen infrequently and affects survival. Diagnosis requires a typical usual interstitial pneumonia (UIP) pattern on computed tomography in the appropriate clinical setting or morphological confirmation of the UIP pattern when imaging findings are not characteristic enough. Surgical lung biopsy is the gold standard to obtain valuable information for histological analysis. However, less invasive procedures (transbronchial lung biopsy or even improved transbronchial lung biopsy by cryoprobes) are now under consideration. Prognostic indicators are mainly derived by pulmonary function tests. Recently, staging systems have been proposed.

Keywords:
Idiopathic pulmonary fibrosis, Interstitial pneumonia, Pulmonary function test, Usual interstitial pneumonia
1.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;15:788-824.
2.
Chilosi M, Doglioni C, Murer B, Poletti V: Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:7-18.
3.
Chilosi M, Poletti V, Murer B, Lestani M, Cancellieri A, Montagna L, Piccoli P, Cangi G, Semenzato G, Doglioni C: Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002;82:1335-1345.
4.
Carloni A, Poletti V, Fermo L, Bellomo V, Chilosi M: Heterogeneous distribution of mechanical stress in human lung: a mathematical approach to evaluate abnormal remodeling in IPF. J Theor Biol 2013;332C:136-140.
5.
Vancheri C, Failla M, Crimi N, Raghu G: Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35:496-504.
6.
Chilosi M, Poletti V, Rossi A: The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res 2012;11:13.
7.
American Thoracic Society, European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
8.
Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8-22.
9.
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66:462-467.
10.
Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
11.
Kim DS, Collard HR, King TE Jr: Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285-292.
12.
Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:242-248.
13.
Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA 3rd, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA: Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-1152.
14.
Marshall RP, Puddicombe A, Cookson WO, Laurent GJ: Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000;55:143-146.
15.
Lee HL, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, Limper AH: Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005;127:2034-2041.
16.
Armanios M: Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009;10:45-61.
17.
Leslie KO, Cool CD, Sporn TA, et al: Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012;136:1366-1376.
18.
Selman M, Carrillo G, Estrada A, et al: Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007;2:e482.
19.
Brown AW, Shlobin OA, Weir N, et al: Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest 2012;142:1005-1010.
20.
Park SO, Seo JB, Kim N, Lee YK, Kim DS: Comparison of usual interstitial pneumonia and nonspecific interstitial pneumonia: quantification of disease severity and discrimination between two diseases on HRCT using a texture-based automated system. Korean J Radiol 2011;12:297-307.
21.
Cha SI, Chang CS, Kim EK, et al: Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 2012;61:98-106.
22.
Kahloon RA, Xue J, Bhargava A, et al: Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013;187:768-775.
23.
Gilani SR, Vuga LJ, Lindell KO, et al: CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010;5:e8959.
24.
Ando M, Miyazaki E, Ishii T, et al: Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013;107:608-615.
25.
Cottin V, Nunes H, Brillet PY, et al: Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM OP). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-593.
26.
Ryerson CJ, Hartman T, Elicker BM, et al: Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013, E-pub ahead of print.
27.
Park J, Kim DS, Shim TS, et al: Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir 2001;17:1216-1219.
28.
Kondoh Y, Taniguchi H, Ogura T, et al: Disease progression in idiopathic pulmonary fibrosis without pulmonary function impairment. Respirology 2013, E-pub ahead of print.
29.
Cordier JF, Cottin V: Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J 2013, E-pub ahead of print.
30.
Sverzellati N, Guerci L, Randi G, et al: Interstitial lung diseases in a lung cancer screening trial. Eur Respir J 2011;38:392-400.
31.
Ambrosini V, Cancellieri A, Chilosi M, et al: Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821-826.
32.
Song JW, Hong SB, Lim CM, Koh Y, Kim DS: Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-363.
33.
Tcherakian C, Cottin V, Brillet PY, et al: Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-231.
34.
Judge EP, Fabre A, Adamali HI, Egan JJ: Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012;40:93-100.
35.
Kondoh Y, Tanigichi H, Katsuta T, et al: Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:103-110.
36.
Suzuki H, Sekine Y, Yoshida S, et al: Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 2011;41:914-921.
37.
Cottin V: Clinical year in review: interstitial lung disease. Eur Respir Rev 2013;22:26-32.
38.
Akira M, Kozuka T, Yamamoto S, Sakatani M: Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:372-378.
39.
Du Bois RM: An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012;21:141-146.
40.
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International Consensus Statement. Am J Respir Crit Care Med 2000;161:646-664.
41.
Hansell DM, Bankier AA, Macmahon H, McLoud TC, Muller NL, Remy J: Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
42.
Sverzellati N, Wells AU, Tomassetti S, et al: Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010;254:957-964.
43.
Fell CD, Martinez FJ, Liu LX, et al: Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832.
44.
Gruden JF, Panse PM, Leslie KO, Tazelaar HD, Colby TV: UIP diagnosed at surgical lung biopsy, 2000-2009: HRCT patterns and proposed classification system. AJR Am J Roentgenol 2013;200:W458-W467.
45.
Kaarteenaho R: The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res 2013;14:43.
46.
Blanco M, Obeso GA, Duran JC, Rivo JE, Garcia-Fontan E, Pena E, Rodriguez M, Abort J, Canizares MA: Surgical lung biopsy for diffuse lung disease. Our experience in the last 15 years. Rev Port Pneumol 2013;19:59-64.
47.
Utz JP, Rye JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2011;17:175-179.
48.
Blackhall V, Asif M, Renieri A, Civitelli S, Kirk A, Jilaihawi A, Granato F: The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK. Interact Cardiovasc Thorac Surg 2013, E-pub ahead of print.
49.
Piciucchi S, Tomassetti S, Casoni G, et al: High resolution CT and histologic findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. Respir Res 2011;12:11.
50.
Reddy TL, Tominaga M, Hansell DM, et al: Pleuroparenchymal fibroelastosis: a spectrum of histopathologic and imaging phenotypes. Eur Respir J 2012;40:377-385.
51.
Churg A, Myers J, Suarez T, et al: Airway-centered interstitial fibrosis: a distinct form of aggressive diffuse lung disease. Am J Surg Pathol 2004;28:62-68.
52.
Takemura T, Akashi T, Kamiya H, et al: Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology 2012;61:1026-1035.
53.
Romagnoli M, Nannini C, Piciucchi S, et al: Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J 2011;38:384-391.
54.
Poletti V, Romagnoli M, Piciucchi S, Chilosi M: Current status of idiopathic interstitial pneumonia. Semin Respir Crit Care Med 2012;33:440-449.
55.
Poletti V, Patelli M, Poggi S, Bertanti T, Spiga L, Ferracini R: Transbronchial lung biopsy and bronchoalveolar lavage in diagnosis of diffuse infiltrative lung diseases. Respiration 1988;54(suppl 1):66-72.
56.
Poletti V, Chilosi M, Olivieri D: Diagnostic invasive procedures in diffuse linfiltrative lung diseases. Respiration 2004;71:107-119.
57.
Berbescu EA, Katzenstein AL, Snow JL, Zisman DA: Transbronchial biopsy in usual interstitial pneumonia. Chest 2006;129:1126-1131.
58.
Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V: Transbronchial biopsy is useful in predicting UIP pattern. Respir Res 2012;13:96.
59.
Nicholson AG, Addis BJ, Bharucha H, et al: Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-505.
60.
Chilosi M, Poletti V, Murer B, et al: Abnormal re-epithelialization and lung remodelling in idiopathic pulmonary fibrosis. Lab Invest 2002;82:1335-1345.
61.
Ohshimo S, Bonella F, Cui A, et al: Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:1043-1047.
62.
du Bois RM: An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012;21:141-146.
63.
Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
64.
du Bois RM, Weeycher D, Albera C, et al: Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-466.
65.
Cottin V: Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012;21:161-167.
66.
Du Bois RM, Weycker D, Albera C, et al: Six-minute-walk test in idiopathic pulmonary fibrosis test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-1237.
67.
Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L: Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is enemy of the good. Thorax 2012;67:938-940.
68.
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR: A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-691.
69.
Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, Collard HR: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407-411.
70.
Collard HR, King TE Jr, Bartelson BB, et al: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
71.
Caminati A, Bianchi A, Cassandro R, et al: Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103:117-123.
72.
Kimura M, Tanigichi H, Kondoh Y, et al: Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013;85:456-463.
73.
Caminati A, Harari S: IPF: new insight in diagnosis and prognosis. Respir Med 2010;104(suppl 1):S2-S10.
74.
Song JW, Song JK, Kim DS: Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009;103:180-186.
75.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd, Martinez FJ: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548.
76.
Du Bois R, Albera C, Bradford W, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM, INSPIRE Study Group: Percent predicted forced vital capacity (FVC) is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF). Eur Resp J 2010;36(suppl 54): 646s.
77.
Mura M, Porretta MA, Bargagli E, et al: Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012;40:101-109.
78.
Vij R, Noth I: Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012;159:218-227.
79.
Richards TJ, Kaminski N, Baribaud F, et al: Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185:67-76.
80.
Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012;18:441-446.
81.
Yang IV, Luna LG, Cotter J, et al: The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One 2012;76:e37708.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.